Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? (Revised)

Core Viewpoint - Pfizer is well-positioned to continue its earnings-beat streak in the upcoming report, having surpassed earnings estimates significantly in the last two quarters [1]. Earnings Performance - In the most recent quarter, Pfizer reported earnings of $0.78 per share, exceeding the expected $0.58 per share by 34.48% [2]. - For the previous quarter, Pfizer's earnings were $0.92 per share against an estimate of $0.64 per share, resulting in a surprise of 43.75% [2]. Earnings Estimates and Predictions - Estimates for Pfizer have been trending higher due to its history of earnings surprises, with a positive Zacks Earnings ESP of +2.53%, indicating bullish sentiment among analysts regarding its near-term earnings potential [5][8]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing that stocks with this combination beat estimates nearly 70% of the time [6][8]. Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate than earlier predictions [7]. - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [9]. Importance of Earnings ESP - Companies often beat consensus EPS estimates, but this is not the only factor influencing stock price movements. Therefore, checking a company's Earnings ESP before quarterly releases is crucial for investment decisions [10].